Navigation Links
Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
Date:11/8/2010

loped a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega 3 products currently available.  Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's Disease patients with normal triglyceride levels for greater than or equal to 52 weeks; approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile.

About Hypertriglyceridemia Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with over 27 million of those diagnosed with hypertriglyceridemia (TGs greater than 200mg/dL) and an estimated 5 million with very high triglyceride levels (TGs greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty a
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 CSSi, the leader in patient ... the formation of the company,s Medical and Clinical Advisory ... of Dr. William E. Gannon, Jr. to ... The MCAB, with Dr. Gannon,s leadership, ... areas and set strategic goals for the advancement and ...
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
(Date:8/18/2014)... NEW YORK , August 18, 2014 /PRNewswire/ ... report published by Transparency Market Research "Life Science ... Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents ... Research and Academic Institutions, Clinical Laboratories, and Forensic ... and Forecast, 2013 - 2019", the global life ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... Institute of Standards and Technology (NIST) may have ... of computer memory now under development. The work, ... University (GMU), aims to optimize nanowire-based charge-trapping memory ... computers and cell phones that can operate for ...
... DIEGO, May 25, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of hepatitis C, announced today that it ... ANA773, the Company,s oral immuno-modulator that acts via the TLR-7 ... Annual Meeting in Chicago, IL.  The data from the completed ...
... 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading ... it has entered into definitive agreements with three ... LLC, Deerfield Management and Merlin Nexus, and certain ... $30.4 million private placement financing of equity and ...
Cached Biology Technology:NIST 'nanowire' measurements could improve computer memory 2Anadys Highlights ANA773 Data to be Presented at ASCO 2Anadys Highlights ANA773 Data to be Presented at ASCO 3Anadys Highlights ANA773 Data to be Presented at ASCO 4WaferGen Announces $30 Million Financing 2WaferGen Announces $30 Million Financing 3WaferGen Announces $30 Million Financing 4
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... warning and can quickly become life threatening for some children. ... many as 1.2 million Canadians have food allergies and this ... per cent of children are estimated to have food allergies.  ... from mild skin irritations and hives to breathing difficulties and ...
(Date:8/20/2014)... University, the Wellcome Trust Sanger Institute and the Swiss ... Mycobacterium pinnipedii from skeletons found in Peru which ... a relative of the TB bacterium that affects seals ... researchers assume that seals carried the pathogens from Africa ... was unexpected" comments Sebastien Gagneux, from the Swiss Tropical ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... researchers are among a select group of scientists from ... National Cancer Institute (NCI) for their quest to answer ... Professor and Chair of Oncological Sciences and Ross Cagan, ... received the NCI,s new "Provocative Questions" grant, which was ...
... 2012 Novetta Solutions, LLC (Novetta), a portfolio ... acquisition of International Biometric Group, LLC (IBG). Novetta ... within the National Security community and other organizations ... established in March 2012 through the merger of ...
... can play a key role in feeding people and restoring their ... during their little-known involvement in the liberation of Bergen-Belsen at the ... a historical research paper published in the October issue of the ... been written about the role of the armed forces and medical ...
Cached Biology News:Mount Sinai researchers awarded 'Provocative Questions' grant from National Cancer Institute 2Mount Sinai researchers awarded 'Provocative Questions' grant from National Cancer Institute 3Novetta Solutions Acquires International Biometric Group, LLC 2Novetta Solutions Acquires International Biometric Group, LLC 3Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 2Bergen-Belsen lessons underline vital role that nurses can play in patient feeding 3
... 94kDa ultra-pure recombinant thermostable DNA polymerase obtained ... DNA polymerase gene in E. coli, Concentration: ... of Thermo Fisher Scientific, the world leader ... customers to make the world healthier, cleaner ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
Biology Products: